Source-grounded facts extracted from Atara Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..
“On February 3, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.”
Atara Biotherapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022, EPS $0.72 per share, and ... $2.24 per share.
“On February 8, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) announced certain financial results for the fourth quarter and year ended December 31, 2022.”
Eric Hyllengren was appointed as Senior Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..
“the Company appointed Eric Hyllengren, the Company’s Senior Vice President, Finance, to serve as the Company’s Senior Vice President, Chief Financial Officer, effective as of April 1, 2023.”
Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..
“Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company, effective March 31, 2023, to pursue an external opportunity.”
Atara Biotherapeutics, Inc. incurred debt of $31,000,000, net of certain transaction costs with HCR Molag Fund, L.P..
“On December 30, 2022, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), and HCR Molag Fund, L.P., a Delaware limited partnership (“HCR”), closed the transactions contemplated by that certain Purchase and Sale Agreement dated December 20, 2022 by and between the Company and HCR.”
Atara Biotherapeutics, Inc. entered into Purchase and Sale Agreement with HCR Molag Fund, L.P. valued at $31,000,000 (effective 2022-12-20).
“On December 20, 2022, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), entered into a purchase and sale agreement (the “Purchase and Sale Agreement”) by and between the Company and HCR Molag Fund, L.P., a Delaware limited partnership (“HCR”), pursuant to which HCR agreed to pay $31,000,000 in cash to the Company in consideration for the Company’s right to receive a portion of future royalty payments and certain milestones for Ebvallo TM (tabelecleucel) in Europe due to the Company from Pierre Fabre Medicament (“Pierre Fabre”) under the terms of the Company’s Commercialization Agreement with Pierre Fabre, dated October 2021, as amended by Amendment No. 1 to the Commercialization Agreement dated September 27, 2022 (the “Commercialization Agreement”).”
Carol D. Gallagher was appointed as Chair of the Board at Atara Biotherapeutics, Inc..
“In addition, effective as of December 19, 2022, the Board appointed Carol D. Gallagher, Pharm D., an independent member of the Board, to succeed Mr. Renaud as Chair of the Board and, in accordance with Section 16 of the Company’s Second Amended and Restated Bylaws, reduced the number of directors on the Board from ten to eight directors.”
Roy Baynes resigned as Director at Atara Biotherapeutics, Inc..
“Also on December 16, 2022, Roy Baynes notified the Company of his resignation from the Board, effective as of December 19, 2022.”
Ronald C. Renaud resigned as Director at Atara Biotherapeutics, Inc..
“On December 16, 2022, Ronald C. Renaud notified Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), of his resignation from the Board of Directors of the Company (the “Board”), effective as of December 19, 2022.”
Atara Biotherapeutics, Inc. reported financial results for the third quarter 2022.
“Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.”
Kristin Yarema was terminated as Senior Vice President and Chief Commercial Officer at Atara Biotherapeutics, Inc..
“the employment of Kristin Yarema, the Company’s Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022.”
Joseph Newell changed role as Executive Vice President and Chief Operations Officer at Atara Biotherapeutics, Inc..
“In connection with the entry into the Asset Purchase Agreement and effective as of January 31, 2022, Joseph Newell, the Company’s Executive Vice President and Chief Operations Officer, will transition from being an employee of the Company and become a consultant.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.